论文部分内容阅读
目的:评价奥硝唑与法莫替丁联用治疗慢性胃炎患者的临床疗效和安全性。方法:选取2012年1月—2014年1月间诊治的慢性胃炎患者200例,根据收治先后顺序的单双号,将其分为观察组(n=100)和对照组(n=100);对照组患者予口服法莫替丁治疗,观察组患者予奥硝唑与法莫替丁联用治疗,经治疗4周后评价两组患者的临床疗效及不良反应,随访半年观察复发情况。结果:观察组患者治疗后总有效率为95.00%显著高于对照组87.00%(P<0.05);前者不良反应发生率为2.00%低于对照组为7.00%;随访半年发现观察组患者复发率为6.00%显著低于对照组为14.00%(P<0.05)。结论:奥硝唑与法莫替丁联用于治疗慢性胃炎的临床疗效较为确切,不良反应发生率较低。
Objective: To evaluate the clinical efficacy and safety of ornidazole combined with famotidine in the treatment of patients with chronic gastritis. Methods: A total of 200 patients with chronic gastritis diagnosed and treated between January 2012 and January 2014 were selected and divided into observation group (n = 100) and control group (n = 100) according to the sequence of single and double numbers. Patients in the control group were treated with famotidine orally. Patients in the observation group were given either ornidazole combined with famotidine. After 4 weeks of treatment, the clinical efficacy and adverse reactions of the two groups were evaluated and the recurrence was observed for six months. Results: The total effective rate in observation group was 95.00%, which was significantly higher than that in control group (87.00%, P <0.05). The incidence of adverse reactions was 2.00% in the former group and 7.00% in the control group. The recurrence rate was observed in the observation group 6.00% was significantly lower than the control group was 14.00% (P <0.05). Conclusion: The clinical efficacy of ornidazole combined with famotidine in the treatment of chronic gastritis is more accurate and the incidence of adverse reactions is lower.